SCENESSE

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, Ireland, Italy, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug SCENESSE contains one active pharmaceutical ingredient (API):

1	Afamelanotide UNII QW68W3J66U - AFAMELANOTIDE
	Afamelanotide is a synthetic tridecapeptide and a structural analogue of α-melanocyte stimulating hormone (α-MSH). Afamelanotide is a melanocortin receptor agonist and binds predominantly to the melanocortin-1 receptor (MC1R). Afamelanotide is thought to mimic the endogenous compound’s pharmacological activity by activating the synthesis of eumelanin mediated by the MC1R receptor. Eumelanin contributes to photoprotection through different mechanisms.
	Read more about Afamelanotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SCENESSE Implant	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D02BB02		D Dermatologicals → D02 Emollients and protectives → D02B Protectives against UV-radiation → D02BB Protectives against UV-radiation for systemic use
Discover more medicines within D02BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1673928
FI	Lääkealan turvallisuus- ja kehittämiskeskus	393360
IT	Agenzia del Farmaco	043798014
LT	Valstybinė vaistų kontrolės tarnyba	1075287
NL	Z-Index G-Standaard, PRK	134384
PL	Rejestru Produktów Leczniczych	100334761
US	FDA, National Drug Code	73372-0116